Eli Lilly and - LLY Stock Forecast, Price & News

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Eli Lilly and Price Performance

NYSE:LLY opened at $313.94 on Tuesday. The stock has a market capitalization of $298.30 billion, a P/E ratio of 50.07, a P/E/G ratio of 2.10 and a beta of 0.35. Eli Lilly and has a 1 year low of $220.20 and a 1 year high of $335.33. The business's fifty day moving average is $315.66 and its two-hundred day moving average is $292.40. The company has a debt-to-equity ratio of 1.70, a quick ratio of 0.85 and a current ratio of 1.10.

Eli Lilly and (NYSE:LLY - Get Rating) last posted its quarterly earnings data on Thursday, August 4th. The company reported $1.25 earnings per share for the quarter, missing the consensus estimate of $1.86 by ($0.61). Eli Lilly and had a return on equity of 85.58% and a net margin of 19.58%. The firm had revenue of $6.49 billion for the quarter, compared to analysts' expectations of $6.85 billion. During the same quarter in the previous year, the firm posted $1.87 earnings per share. The company's revenue for the quarter was down 3.7% on a year-over-year basis. On average, research analysts forecast that Eli Lilly and will post 7.96 earnings per share for the current fiscal year.

Eli Lilly and Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, September 9th. Stockholders of record on Monday, August 15th will be issued a dividend of $0.98 per share. This represents a $3.92 annualized dividend and a dividend yield of 1.25%. The ex-dividend date of this dividend is Friday, August 12th. Eli Lilly and's dividend payout ratio is currently 62.52%.

Analyst Upgrades and Downgrades

A number of research firms have commented on LLY. Mizuho lifted their target price on Eli Lilly and from $315.00 to $356.00 in a report on Monday, May 2nd. StockNews.com cut Eli Lilly and from a "strong-buy" rating to a "buy" rating in a research note on Friday, August 5th. JPMorgan Chase & Co. boosted their target price on Eli Lilly and from $340.00 to $355.00 in a research report on Wednesday, June 1st. Morgan Stanley boosted their price target on Eli Lilly and from $369.00 to $395.00 and gave the company an "overweight" rating in a report on Friday, July 8th. Finally, Wells Fargo & Company upped their target price on Eli Lilly and from $280.00 to $305.00 in a research report on Friday, April 29th. Three investment analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $317.00.

Insider Activity

In other news, SVP Alonzo Weems sold 656 shares of the business's stock in a transaction on Wednesday, August 10th. The shares were sold at an average price of $304.50, for a total transaction of $199,752.00. Following the transaction, the senior vice president now directly owns 8,136 shares in the company, valued at approximately $2,477,412. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. In other Eli Lilly and news, SVP Alonzo Weems sold 656 shares of the business's stock in a transaction on Wednesday, August 10th. The shares were sold at an average price of $304.50, for a total transaction of $199,752.00. Following the completion of the transaction, the senior vice president now owns 8,136 shares of the company's stock, valued at approximately $2,477,412. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, major shareholder Lilly Endowment Inc sold 700 shares of the company's stock in a transaction dated Wednesday, May 18th. The shares were sold at an average price of $302.00, for a total transaction of $211,400.00. Following the transaction, the insider now directly owns 105,472,666 shares of the company's stock, valued at approximately $31,852,745,132. The disclosure for this sale can be found here. Insiders have sold a total of 1,115,291 shares of company stock worth $355,901,728 in the last ninety days. Corporate insiders own 0.12% of the company's stock.